Filgrastim Market

Global Filgrastim Market By Drug Type (Biosimilar and Biologic), By Indication (Chemotherapy induced Neutropenia, Chronic Neutropenia and Other Indications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Regional Outlook, Industry Analysis Report and Forecast, 2021 - 2027

Report Id: KBV-7057 Publication Date: December-2021 Number of Pages: 193
Special Offering:
Industry Insights | Market Trends
Highest number of Tables | 24/7 Analyst Support
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Filgrastim Market, by Drug Type
1.4.2 Global Filgrastim Market, by Indication
1.4.3 Global Filgrastim Market, by Distribution Channel
1.4.4 Global Filgrastim Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Global Filgrastim Market by Drug Type
3.1 Global Biosimilar Market by Region
3.2 Global Biologic Market by Region

Chapter 4. Global Filgrastim Market by Indication
4.1 Global Chemotherapy induced Neutropenia Market by Region
4.2 Global Chronic Neutropenia Market by Region
4.3 Global Other Indications Market by Region

Chapter 5. Global Filgrastim Market by Distribution Channel
5.1 Global Hospital Pharmacies Market by Region
5.2 Global Retail Pharmacies Market by Region
5.3 Global Online Pharmacies Market by Region

Chapter 6. Global Filgrastim Market by Region
6.1 North America Filgrastim Market
6.1.1 North America Filgrastim Market by Drug Type
6.1.1.1 North America Biosimilar Market by Country
6.1.1.2 North America Biologic Market by Country
6.1.2 North America Filgrastim Market by Indication
6.1.2.1 North America Chemotherapy induced Neutropenia Market by Country
6.1.2.2 North America Chronic Neutropenia Market by Country
6.1.2.3 North America Other Indications Market by Country
6.1.3 North America Filgrastim Market by Distribution Channel
6.1.3.1 North America Hospital Pharmacies Market by Country
6.1.3.2 North America Retail Pharmacies Market by Country
6.1.3.3 North America Online Pharmacies Market by Country
6.1.4 North America Filgrastim Market by Country
6.1.4.1 US Filgrastim Market
6.1.4.1.1 US Filgrastim Market by Drug Type
6.1.4.1.2 US Filgrastim Market by Indication
6.1.4.1.3 US Filgrastim Market by Distribution Channel
6.1.4.2 Canada Filgrastim Market
6.1.4.2.1 Canada Filgrastim Market by Drug Type
6.1.4.2.2 Canada Filgrastim Market by Indication
6.1.4.2.3 Canada Filgrastim Market by Distribution Channel
6.1.4.3 Mexico Filgrastim Market
6.1.4.3.1 Mexico Filgrastim Market by Drug Type
6.1.4.3.2 Mexico Filgrastim Market by Indication
6.1.4.3.3 Mexico Filgrastim Market by Distribution Channel
6.1.4.4 Rest of North America Filgrastim Market
6.1.4.4.1 Rest of North America Filgrastim Market by Drug Type
6.1.4.4.2 Rest of North America Filgrastim Market by Indication
6.1.4.4.3 Rest of North America Filgrastim Market by Distribution Channel
6.2 Europe Filgrastim Market
6.2.1 Europe Filgrastim Market by Drug Type
6.2.1.1 Europe Biosimilar Market by Country
6.2.1.2 Europe Biologic Market by Country
6.2.2 Europe Filgrastim Market by Indication
6.2.2.1 Europe Chemotherapy induced Neutropenia Market by Country
6.2.2.2 Europe Chronic Neutropenia Market by Country
6.2.2.3 Europe Other Indications Market by Country
6.2.3 Europe Filgrastim Market by Distribution Channel
6.2.3.1 Europe Hospital Pharmacies Market by Country
6.2.3.2 Europe Retail Pharmacies Market by Country
6.2.3.3 Europe Online Pharmacies Market by Country
6.2.4 Europe Filgrastim Market by Country
6.2.4.1 Germany Filgrastim Market
6.2.4.1.1 Germany Filgrastim Market by Drug Type
6.2.4.1.2 Germany Filgrastim Market by Indication
6.2.4.1.3 Germany Filgrastim Market by Distribution Channel
6.2.4.2 UK Filgrastim Market
6.2.4.2.1 UK Filgrastim Market by Drug Type
6.2.4.2.2 UK Filgrastim Market by Indication
6.2.4.2.3 UK Filgrastim Market by Distribution Channel
6.2.4.3 France Filgrastim Market
6.2.4.3.1 France Filgrastim Market by Drug Type
6.2.4.3.2 France Filgrastim Market by Indication
6.2.4.3.3 France Filgrastim Market by Distribution Channel
6.2.4.4 Russia Filgrastim Market
6.2.4.4.1 Russia Filgrastim Market by Drug Type
6.2.4.4.2 Russia Filgrastim Market by Indication
6.2.4.4.3 Russia Filgrastim Market by Distribution Channel
6.2.4.5 Spain Filgrastim Market
6.2.4.5.1 Spain Filgrastim Market by Drug Type
6.2.4.5.2 Spain Filgrastim Market by Indication
6.2.4.5.3 Spain Filgrastim Market by Distribution Channel
6.2.4.6 Italy Filgrastim Market
6.2.4.6.1 Italy Filgrastim Market by Drug Type
6.2.4.6.2 Italy Filgrastim Market by Indication
6.2.4.6.3 Italy Filgrastim Market by Distribution Channel
6.2.4.7 Rest of Europe Filgrastim Market
6.2.4.7.1 Rest of Europe Filgrastim Market by Drug Type
6.2.4.7.2 Rest of Europe Filgrastim Market by Indication
6.2.4.7.3 Rest of Europe Filgrastim Market by Distribution Channel
6.3 Asia Pacific Filgrastim Market
6.3.1 Asia Pacific Filgrastim Market by Drug Type
6.3.1.1 Asia Pacific Biosimilar Market by Country
6.3.1.2 Asia Pacific Biologic Market by Country
6.3.2 Asia Pacific Filgrastim Market by Indication
6.3.2.1 Asia Pacific Chemotherapy induced Neutropenia Market by Country
6.3.2.2 Asia Pacific Chronic Neutropenia Market by Country
6.3.2.3 Asia Pacific Other Indications Market by Country
6.3.3 Asia Pacific Filgrastim Market by Distribution Channel
6.3.3.1 Asia Pacific Hospital Pharmacies Market by Country
6.3.3.2 Asia Pacific Retail Pharmacies Market by Country
6.3.3.3 Asia Pacific Online Pharmacies Market by Country
6.3.4 Asia Pacific Filgrastim Market by Country
6.3.4.1 China Filgrastim Market
6.3.4.1.1 China Filgrastim Market by Drug Type
6.3.4.1.2 China Filgrastim Market by Indication
6.3.4.1.3 China Filgrastim Market by Distribution Channel
6.3.4.2 Japan Filgrastim Market
6.3.4.2.1 Japan Filgrastim Market by Drug Type
6.3.4.2.2 Japan Filgrastim Market by Indication
6.3.4.2.3 Japan Filgrastim Market by Distribution Channel
6.3.4.3 India Filgrastim Market
6.3.4.3.1 India Filgrastim Market by Drug Type
6.3.4.3.2 India Filgrastim Market by Indication
6.3.4.3.3 India Filgrastim Market by Distribution Channel
6.3.4.4 South Korea Filgrastim Market
6.3.4.4.1 South Korea Filgrastim Market by Drug Type
6.3.4.4.2 South Korea Filgrastim Market by Indication
6.3.4.4.3 South Korea Filgrastim Market by Distribution Channel
6.3.4.5 Singapore Filgrastim Market
6.3.4.5.1 Singapore Filgrastim Market by Drug Type
6.3.4.5.2 Singapore Filgrastim Market by Indication
6.3.4.5.3 Singapore Filgrastim Market by Distribution Channel
6.3.4.6 Malaysia Filgrastim Market
6.3.4.6.1 Malaysia Filgrastim Market by Drug Type
6.3.4.6.2 Malaysia Filgrastim Market by Indication
6.3.4.6.3 Malaysia Filgrastim Market by Distribution Channel
6.3.4.7 Rest of Asia Pacific Filgrastim Market
6.3.4.7.1 Rest of Asia Pacific Filgrastim Market by Drug Type
6.3.4.7.2 Rest of Asia Pacific Filgrastim Market by Indication
6.3.4.7.3 Rest of Asia Pacific Filgrastim Market by Distribution Channel
6.4 LAMEA Filgrastim Market
6.4.1 LAMEA Filgrastim Market by Drug Type
6.4.1.1 LAMEA Biosimilar Market by Country
6.4.1.2 LAMEA Biologic Market by Country
6.4.2 LAMEA Filgrastim Market by Indication
6.4.2.1 LAMEA Chemotherapy induced Neutropenia Market by Country
6.4.2.2 LAMEA Chronic Neutropenia Market by Country
6.4.2.3 LAMEA Other Indications Market by Country
6.4.3 LAMEA Filgrastim Market by Distribution Channel
6.4.3.1 LAMEA Hospital Pharmacies Market by Country
6.4.3.2 LAMEA Retail Pharmacies Market by Country
6.4.3.3 LAMEA Online Pharmacies Market by Country
6.4.4 LAMEA Filgrastim Market by Country
6.4.4.1 Brazil Filgrastim Market
6.4.4.1.1 Brazil Filgrastim Market by Drug Type
6.4.4.1.2 Brazil Filgrastim Market by Indication
6.4.4.1.3 Brazil Filgrastim Market by Distribution Channel
6.4.4.2 Argentina Filgrastim Market
6.4.4.2.1 Argentina Filgrastim Market by Drug Type
6.4.4.2.2 Argentina Filgrastim Market by Indication
6.4.4.2.3 Argentina Filgrastim Market by Distribution Channel
6.4.4.3 UAE Filgrastim Market
6.4.4.3.1 UAE Filgrastim Market by Drug Type
6.4.4.3.2 UAE Filgrastim Market by Indication
6.4.4.3.3 UAE Filgrastim Market by Distribution Channel
6.4.4.4 Saudi Arabia Filgrastim Market
6.4.4.4.1 Saudi Arabia Filgrastim Market by Drug Type
6.4.4.4.2 Saudi Arabia Filgrastim Market by Indication
6.4.4.4.3 Saudi Arabia Filgrastim Market by Distribution Channel
6.4.4.5 South Africa Filgrastim Market
6.4.4.5.1 South Africa Filgrastim Market by Drug Type
6.4.4.5.2 South Africa Filgrastim Market by Indication
6.4.4.5.3 South Africa Filgrastim Market by Distribution Channel
6.4.4.6 Nigeria Filgrastim Market
6.4.4.6.1 Nigeria Filgrastim Market by Drug Type
6.4.4.6.2 Nigeria Filgrastim Market by Indication
6.4.4.6.3 Nigeria Filgrastim Market by Distribution Channel
6.4.4.7 Rest of LAMEA Filgrastim Market
6.4.4.7.1 Rest of LAMEA Filgrastim Market by Drug Type
6.4.4.7.2 Rest of LAMEA Filgrastim Market by Indication
6.4.4.7.3 Rest of LAMEA Filgrastim Market by Distribution Channel

Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.2 Amgen, Inc.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.3 Pfizer, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expense
7.3.5 Recent strategies and developments:
7.3.5.1 Approvals and Trials:
7.4 Novartis AG
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Product Launches and Product Expansions:
7.5 Dr. Reddy’s Laboratories Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.5.5.2 Product Launches and Product Expansions:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 Recent strategies and developments:
7.6.5.1 Approvals and Trials:
7.7 Kyowa Kirin Co., Ltd. (Kirin Company)
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.8 Cadila Healthcare Ltd. (Zydus Cadila)
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expense
7.9 Apotex, Inc.
7.9.1 Company Overview
7.9.2 Recent strategies and developments:
7.9.2.1 Product Launches and Product Expansions:
7.10 Toksöz Group
7.10.1 Company Overview
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale

Trusted by over
5000+ clients

Our team of dedicated experts can provide you with attractive expansion opportunities for your business.

Client Logo